SAGE Therapeutics (SAGE) Raised to “Sell” at BidaskClub

BidaskClub upgraded shares of SAGE Therapeutics (NASDAQ:SAGE) from a strong sell rating to a sell rating in a report published on Friday.

Several other research firms have also issued reports on SAGE. LADENBURG THALM/SH SH set a $235.00 price target on SAGE Therapeutics and gave the company a buy rating in a report on Wednesday, October 31st. Morgan Stanley boosted their price target on SAGE Therapeutics from $225.00 to $228.00 and gave the company an overweight rating in a report on Friday, July 13th. Cowen reissued a buy rating and set a $207.00 price target on shares of SAGE Therapeutics in a report on Thursday. Oppenheimer set a $170.00 price target on SAGE Therapeutics and gave the company a buy rating in a report on Monday, October 29th. Finally, Stifel Nicolaus boosted their price target on SAGE Therapeutics from $198.00 to $239.00 and gave the company a buy rating in a report on Tuesday, August 7th. Two investment analysts have rated the stock with a sell rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company. The company currently has a consensus rating of Buy and a consensus price target of $204.81.

NASDAQ:SAGE traded down $8.74 during mid-day trading on Friday, hitting $128.81. 602,515 shares of the company traded hands, compared to its average volume of 385,450. SAGE Therapeutics has a one year low of $59.65 and a one year high of $195.97. The firm has a market capitalization of $6.42 billion, a PE ratio of -18.17 and a beta of 2.76.

SAGE Therapeutics (NASDAQ:SAGE) last released its quarterly earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.84) by $1.48. The company had revenue of $90.00 million for the quarter. On average, equities analysts anticipate that SAGE Therapeutics will post -7.32 earnings per share for the current year.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. WINTON GROUP Ltd boosted its stake in shares of SAGE Therapeutics by 24.6% in the third quarter. WINTON GROUP Ltd now owns 3,491 shares of the biopharmaceutical company’s stock worth $493,000 after acquiring an additional 689 shares during the period. Wells Fargo & Company MN boosted its stake in shares of SAGE Therapeutics by 39.1% in the third quarter. Wells Fargo & Company MN now owns 388,706 shares of the biopharmaceutical company’s stock worth $54,905,000 after acquiring an additional 109,250 shares during the period. State Board of Administration of Florida Retirement System boosted its stake in shares of SAGE Therapeutics by 1.4% in the third quarter. State Board of Administration of Florida Retirement System now owns 55,242 shares of the biopharmaceutical company’s stock worth $7,803,000 after acquiring an additional 781 shares during the period. Public Employees Retirement Association of Colorado lifted its position in shares of SAGE Therapeutics by 46.4% in the third quarter. Public Employees Retirement Association of Colorado now owns 6,966 shares of the biopharmaceutical company’s stock worth $984,000 after buying an additional 2,209 shares in the last quarter. Finally, Russell Investments Group Ltd. lifted its position in shares of SAGE Therapeutics by 57.8% in the third quarter. Russell Investments Group Ltd. now owns 193,730 shares of the biopharmaceutical company’s stock worth $27,286,000 after buying an additional 70,962 shares in the last quarter.

About SAGE Therapeutics

Sage Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system disorders. Its lead product candidate comprises brexanolone, a proprietary intravenous formulation of allopregnanolone that has completed III clinical trials for the treatment of post-partum depression (PPD).

Featured Article: Stock Symbol

Analyst Recommendations for SAGE Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply